Relmada Therapeutics Inc

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Relmada Therapeutics addresses setbacks, remains confident in REL-1017's potential

Relmada Therapeutics faced challenges in Q4 2022 with study results, leading to increased expenses and a net loss. Despite setbacks, the company remains confident in REL-1017's potential and is focused on refining trial protocols for future success.

Relmada Therapeutics reports positive Q1 results and advances MDD treatment

Relmada Therapeutics Inc. demonstrates financial improvement and progress in its REL-1017 program for major depressive disorder. The company's strategic amendments to study protocols and upcoming safety study data release indicate a commitment to advancing its pipeline. Addressing challenges in trial management and regulatory interactions is key to sustaining growth and market success.

Relmada Therapeutics reports improved Q2 financials and advances in key trials

Relmada Therapeutics showcased improved financial performance and progress in key clinical trials during the Q2 2023 Earnings Call.
While challenges like enrollment progress and regulatory feedback exist, the company's adaptability and cash position provide strengths to navigate them.
Opportunities lie in expanding the clinical program, achieving positive trial outcomes, and enhancing investor confidence through transparent communication.

Relmada Therapeutics reports positive Q3 results and advances key programs

Relmada Therapeutics demonstrated strong performance in Q3 2023 with progress in key programs and improved financial metrics.
While facing challenges in expense management and trial timelines, the company's strengths in research and financial discipline position them well for future growth.
Opportunities lie in leveraging positive trial results, attracting investors, and advancing innovative treatments to drive value creation.

Relmada Therapeutics reports progress in Phase III programs and financial stability

Relmada Therapeutics Inc showcased positive performance in its Phase III program and financial results, demonstrating resilience and strategic planning. While challenges exist in enrollment and monitoring, the company's confidence in its products and innovative approach to psilocybin present promising opportunities for growth and development.

Relmada Therapeutics Inc reports strong Q1 performance and pipeline advancements

Relmada Therapeutics Inc reported positive financial performance, progress in key programs, and proactive pipeline expansion in Q1 2024, positioning the company for future growth.
While facing challenges such as increased screening failure rates and competition, Relmada's strategic focus on trial optimization and therapeutic innovation presents opportunities for advancement.
The company's commitment to addressing mental health needs through Phase III trials and novel programs like psilocybin underscores its dedication to driving clinical progress and market differentiation.
With a strong financial position and promising developments in the pipeline, Relmada is poised to navigate challenges, capitalize on opportunities, and drive value for stakeholders.

Relmada Therapeutics advances CNS disorder treatments amidst financial stability

Relmada Therapeutics is making strides in advancing treatments for CNS disorders, with a focus on major depressive disorder. Financially, the company is managing expenses while progressing key programs. Uncertainty around interim analysis outcomes presents challenges, but successful results could open doors to new opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - Chief Executive Officer Cedric O'Gorman - Chief Medical Officer Maged Shenouda - Maged Shenouda Conference Call Participants Rudy Li - SVB Securities Uy Ear - Mizuho Andrew Tsai - Jefferies Andrea Tan - Goldman Sachs Yatin Suneja - Guggenheim Partners Operator Good afternoon. Thank you for attending today's Relmada Therapeutics Inc. First Quarter 2023 Earnings Call.

Relmada Therapeutics, Inc. (RLMD) Q1 2023 Earnings Call Transcript

NEW YORK , May 12, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Relmada Therapeutics, Inc. (NYSE: RLMD) To be contacted by a member of our team, fill out the form: https://claimyourloss.com/securities/relmada-class-action-loss-submission-form/?from=4 Further details on the investigation: Before market opened on October 13, 2022, Relmada announced the results of its RELIANCE III study (REL-1017-303), evaluating the drug REL-1017 as a monotherapy for Major Depressive Disorder (MDD). Relmada revealed that the RELIANCE III trial did not achieve its primary endpoint, which was a statistically significant improvement in depression symptoms compared to placebo on Day 28, as measured by the Mongomery-Asberg Depression Rating Scale (MADRS).

RLMD FRAUD ALERT: Jakubowitz Law is Investigating Relmada Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws

CORAL GABLES, Fla. , May 11, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2023.

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

NEW YORK--(BUSINESS WIRE)---- $RLMD #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Relmada Therapeutics, Inc. (“Relmada” or “the Company”) (NASDAQ: RLMD). Investors who purchased Relmada securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/rlmd. The investigation concerns whether Relmada has violated federal securities laws. On October 13, 2022, Relmad.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Relmada Therapeutics, Inc. (RLMD) Investigation

NEW YORK , May 10, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Relmada Therapeutics, Inc.: Before market opened on October 13, 2022, Relmada announced the results of its RELIANCE III study (REL-1017-303), evaluating the drug REL-1017 as a monotherapy for Major Depressive Disorder (MDD). Relmada revealed that the RELIANCE III trial did not achieve its primary endpoint, which was a statistically significant improvement in depression symptoms compared to placebo on Day 28, as measured by the Mongomery-Asberg Depression Rating Scale (MADRS).

INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Relmada Therapeutics, Inc. of an Investigation and Potential Class Action Lawsuit - (NYSE: RLMD)

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (NYSE: RLMD) on behalf of Relmada stockholders. Our investigation concerns whether Relmada has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. Before market opened on October 13, 2022, Relmada announced th.

RELMADA ALERT: Bragar Eagel & Squire, P.C. is Investigating Relmada Therapeutics, Inc. on Behalf of Relmada Stockholders and Encourages Investors to Contact the Firm

CORAL GABLES, Fla. , May 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2023 after the market close on Thursday, May 11 th, 2023.

Relmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023

NEW YORK , May 4, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Relmada Therapeutics, Inc. ("Relmada" or the "Company") (NYSE: RLMD) concerning possible violations of federal securities laws. Before market opened on October 13, 2022, Relmada announced the results of its RELIANCE III study (REL-1017-303), evaluating the drug REL-1017 as a monotherapy for Major Depressive Disorder (MDD).

RLMD INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Relmada Therapeutics, Inc. (NASDAQ: RLMD) resulting from allegations that Relmada may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Relmada securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran.

RLMD INVESTOR NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMD

NEW YORK , April 28, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Relmada Therapeutics, Inc. ("Relmada" or the "Company") (NYSE: RLMD) concerning possible violations of federal securities laws. Before market opened on October 13, 2022, Relmada announced the results of its RELIANCE III study (REL-1017-303), evaluating the drug REL-1017 as a monotherapy for Major Depressive Disorder (MDD).

RLMD INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $RLMD #RLMD--The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - CEO Maged Shenouda - CFO Cedric O'Gorman - Chief Medical Officer Conference Call Participants Uy Ear - Mizuho Health Guofang Li - SVB Securities Andrea Tan - Goldman Sachs Andrew Tsai - Jefferies Jay Olson - Oppenheimer Operator Greetings and welcome to Relmada Therapeutics Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Relmada Therapeutics, Inc. (RLMD) Q4 2022 Earnings Call Transcript

CORAL GABLES, Fla. , March 23, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full-year ended December 31, 2022.

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

CORAL GABLES, Fla. , March 17, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2022 after the market close on Thursday, March 23, 2023.

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023

CORAL GABLES, Fla. , Jan. 12, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Fabiana Fedeli, Chief Investment Officer Equities, Multi Asset and Sustainability, at M&G Investments, one of the United Kingdom's largest and longest established investment houses, as an independent director to the Company's Board of Directors.

Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors

CORAL GABLES, Fla. , Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Cedric O'Gorman MD as the Company's Chief Medical Officer.

Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer

Shares of Relmada Therapeutics Inc. RLMD, -0.95% tumbled about 40% in premarket trading on Thursday, the day after the company said its experimental depression drug did not meet the primary endpoint in a Phase 3 clinical trial. The stock closed Wednesday at $4.16, a three-year low.

Relmada Therapeutics shares decline 40% on Thursday

Company to Host Conference Call Today, December 7, 2022, at 5:00 PM ET CORAL GABLES, Fla. , Dec. 7, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced results of the RELIANCE I study (REL-1017-301), evaluating REL-1017 as an adjunctive treatment for Major Depressive Disorder (MDD).

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Maurizio Fava - Chairman, Harvard Psychiatry Department Conference Call Participants Guofang Li - SVB Securities Uy Ear - Mizuho Yatin Suneja - Guggenheim Partners Andrea Tan - Goldman Sachs Andrew Tsai - Jefferies Jay Olson - Oppenheimer Joon Lee - Truist Securities Operator Good afternoon. My name is Kathy, and I'll be your conference operator for today.

Relmada Therapeutics, Inc. (RLMD) Q3 2022 Earnings Call Transcript

CORAL GABLES, Fla. , Nov. 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the three and nine months ended September 30, 2022.

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

CORAL GABLES, Fla. , Nov. 8, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter and nine months ended September 30, 2022 after the market close on Thursday, November 10, 2022.

Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022

Immunic Inc

Steven Cohen (Trades, Portfolio), chairman and CEO of Point72 Asset Management, disclosed in regulatory filings that his firm established a position in Progress Acquistion Corp. ( PGRWU , Financial) and boosted its holdings of Relmada Therapeutics Inc. ( RLMD , Financial) and Immunic Inc. ( IMUX , Financial).

Steven Cohen's Firm Boosts Stakes in Relmada and Immunic

Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.

Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study

Source: Shutterstock Relmada Therapeutics (NASDAQ: RLMD ) stock is plummeting on Thursday as investors react to results from a Phase 3 clinical trial. Unfortunately for RLMD stock, its RELIANCE III study didn't go as planned.

Why Is Relmada (RLMD) Stock Down 78% Today?

Relmada stock crashed Thursday after its depression treatment failed a final-phase test, helping bolster rival Axsome. AXSM stock surged.

News for Relmada Therapeutics Inc Stock (RLMD)